Literature DB >> 26184773

Trends of prostate cancer incidence and mortality in Shanghai, China from 1973 to 2009.

Di Qi1,2, Chunxiao Wu3, Fang Liu1,2,4, Kai Gu3, Zhuqing Shi1,2, Xiaoling Lin4, Sha Tao5, Wanghong Xu6, Charles B Brendler7, Ying Zheng3, Jianfeng Xu1,2,4,5,7.   

Abstract

BACKGROUND: The incidence and mortality of prostate cancer (PCa) were historically low in China but have increased considerably in recent years. This study aimed to describe the detailed trend of PCa incidence and mortality in Shanghai, China.
MATERIAL AND METHODS: Incidence and mortality data of PCa in urban Shanghai during 1973 and 2009 were collected by the Shanghai Municipal Center for Disease Control and Prevention. Age standardized rates (ASR) of incidence and mortality were calculated based on the 1966 world standard population. Join point regression analysis was used to describe the trends and to identify specific time points when significant changes in incidence and mortality occurred.
RESULTS: The PCa incidence in Shanghai increased ~sixfold from an ASR of 2.13/100,000 in 1973 to 12.96/100,000 in 2009, and its rank ascended from the 17th to the 4th most common cancer during the period. The PCa mortality in Shanghai increased threefold from an ASR of 1.61/100,000 in 1973 to 4.97/100,000 in 2009, and its rank ascended from the 17th to the 6th most deadly cancer during this period. More specifically, the ASR of incidence increased slightly before 1991, sharply during1991-2004, and slightly after 2004, with annual percent changes (APC) of 2.2% (95% confidence interval: 0.3%-4.3%), 13.2% (11.4%-15.0%), and 3.2% (-0.3%-6.8%), respectively. The mortality trend was stable before 1985 and increased slowly but steadily after 1985, with APC of -0.6% (-4.4%-3.3%) and 5.3% (4.7%-6.0%), respectively. The increasing incidence and mortality rates were primarily observed in men ≥ 70 years.
CONCLUSION: The incidence and mortality of PCa have increased significantly in Shanghai, China over the past four decades.
© 2015 Wiley Periodicals, Inc.

Entities:  

Keywords:  China; Incidence; Mortality; prostate cancer; trend

Mesh:

Year:  2015        PMID: 26184773     DOI: 10.1002/pros.23046

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  23 in total

1.  Prognostic factors in Chinese patients with prostate cancer receiving primary androgen deprivation therapy: validation of Japan Cancer of the Prostate Risk Assessment (J-CAPRA) score and impacts of pre-existing obesity and diabetes mellitus.

Authors:  Meng-Bo Hu; Tian Yang; Ji-Meng Hu; Wen-Hui Zhu; Hao-Wen Jiang; Qiang Ding
Journal:  Int J Clin Oncol       Date:  2018-01-06       Impact factor: 3.402

2.  Assessing cancer-specific anxiety in Chinese men with prostate cancer: psychometric evaluation of the Chinese version of the Memorial Anxiety Scale for Prostate Cancer (MAX-PC).

Authors:  Qingmei Huang; Ping Jiang; Zijun Zhang; Jie Luo; Yun Dai; Li Zheng; Wei Wang
Journal:  Support Care Cancer       Date:  2017-06-22       Impact factor: 3.603

3.  Burden of Prostate Cancer in China, 1990-2019: Findings From the 2019 Global Burden of Disease Study.

Authors:  Fuquan Wang; Chenchen Wang; Haifa Xia; Yun Lin; Dingyu Zhang; Peng Yin; Shanglong Yao
Journal:  Front Endocrinol (Lausanne)       Date:  2022-05-25       Impact factor: 6.055

4.  Propionic Acid-Based PET Imaging of Prostate Cancer.

Authors:  Zhanwen Zhang; Shaoyu Liu; Hui Ma; Xianhong Xiang; Dahong Nie; Ping Hu; Ganghua Tang
Journal:  Mol Imaging Biol       Date:  2021-04-19       Impact factor: 3.488

5.  MTHFR c.677C>T Inhibits Cell Proliferation and Decreases Prostate Cancer Susceptibility in the Han Chinese Population in Shanghai.

Authors:  Jun-Long Wu; Shu-Xian Zhou; Rui Zhao; Xuan Zhang; Kun Chang; Cheng-Yuan Gu; Hua-Lei Gan; Bo Dai; Yao Zhu; Hai-Liang Zhang; Guo-Hai Shi; Yuan-Yuan Qu; Jian-Yuan Zhao; Ding-Wei Ye
Journal:  Sci Rep       Date:  2016-11-07       Impact factor: 4.379

6.  Incidence of breast cancer in Chinese women exposed to the 1959-1961 great Chinese famine.

Authors:  Dandan He; Yuan Fang; Marc J Gunter; Dongli Xu; Yanping Zhao; Jie Zhou; Hong Fang; Wang Hong Xu
Journal:  BMC Cancer       Date:  2017-12-05       Impact factor: 4.430

7.  Low TIM3 expression indicates poor prognosis of metastatic prostate cancer and acts as an independent predictor of castration resistant status.

Authors:  Junlong Wu; Guowen Lin; Yao Zhu; Hailiang Zhang; Guohai Shi; Yijun Shen; Yiping Zhu; Bo Dai; Dingwei Ye
Journal:  Sci Rep       Date:  2017-08-21       Impact factor: 4.379

8.  Race-specific genetic risk score is more accurate than nonrace-specific genetic risk score for predicting prostate cancer and high-grade diseases.

Authors:  Rong Na; Dingwei Ye; Jun Qi; Fang Liu; Xiaoling Lin; Brian T Helfand; Charles B Brendler; Carly Conran; Jian Gong; Yishuo Wu; Xu Gao; Yaqing Chen; S Lilly Zheng; Zengnan Mo; Qiang Ding; Yinghao Sun; Jianfeng Xu
Journal:  Asian J Androl       Date:  2016 Jul-Aug       Impact factor: 3.285

9.  Risk-prediction tools in prostate cancer: the challenge of tailoring.

Authors:  Alessandro Morlacco; Jiahua Pan; R Jeffrey Karnes
Journal:  Asian J Androl       Date:  2016 Nov-Dec       Impact factor: 3.285

10.  Increasing prevalence of familial recurrence of multiple sclerosis in Iran: a population based study of Tehran registry 1999-2015.

Authors:  Sharareh Eskandarieh; Narges Sistany Allahabadi; Malihe Sadeghi; Mohammad Ali Sahraian
Journal:  BMC Neurol       Date:  2018-02-07       Impact factor: 2.474

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.